Introduction to Semaglutide: What Is It? Semaglutide has revolutionized the treatment of type 2 diabetes and obesity as a GLP-1 receptor agonist. Originally developed by Novo Nordisk, it is available under brand names like Ozempic…

Introduction: The Future of Obesity Treatment The pharmaceutical world is abuzz with excitement over Retatrutide, Eli Lilly’s innovative triple-receptor agonist currently in late-stage clinical trials. As the potential successor to blockbuster…

Introduction: A New Hope for Weight Loss In the ever-evolving world of obesity treatment, Retatrutide has emerged as one of the most promising new medications. As the latest development from pharmaceutical giant…

Introduction The pharmaceutical world is buzzing with excitement over Retatrutide, Eli Lilly’s innovative triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors. As the successor to blockbuster drugs like Mounjaro (Tirzepatide) and Wegovy (Semaglutide), Retatrutide promises even greater weight…

? Retatrutide Overview Retatrutide (Eli Lilly’s triple-hormone agonist) is the next-generation obesity and type 2 diabetes treatment, outperforming Wegovy® and Mounjaro® in clinical trials with 24.2% average weight loss at 48 weeks. As…

I. Pharmacological Differences A. Molecular Mechanisms B. Receptor Binding Affinities Receptor Tirzepatide EC50 Semaglutide EC50 GLP-1 0.11 nM 0.04 nM GIP 0.08 nM N/A II. Head-to-Head Clinical Comparisons A. SURPASS-6…